RNA has recently emerged as an important nanotechnology platform due to its extraordinary diversity in structure and function. Small interfering RNA (siRNA), showed significant potential in new molecular approaches to down-regulate specific gene expression in mammalian cells. In fact, targeted gene suppression by antisense DNA and siRNA has shown promising preclinical results, and/or is currently in clinical trials for a variety of diseases, including many forms of cancer (e.g., melanoma, neuroblastoma, and pancreatic adenocarcinoma), genetic disorders, and macular generation . Despite the high therapeutic potential of siRNA, its application for clinical medicine is still limited mainly due to the lack of appropriate delivery systems. In such a situation, the development of clinically suitable, safe, and effective drug-delivery biomaterials are required for the widespread use of siRNA therapeutics for disease treatment. OMICS Group through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS Group hosts over 700+ peer-reviewed journals and has organized over 3000+ International Scientific Conferences all over the world. OMICS International is has wide classification of journals and Molecular Biology is one of the important of them. Molecular Biology covers each and every aspect of gene studies from the very basic to the new advance.
Last date updated on July, 2014